Intervacc (OM:IVACC) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

IVACC Aperçu des actions

Intervacc AB (publ) développe de nouveaux vaccins vétérinaires pour les animaux en Suède.

IVACC analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 78.7% par an

Analyse des risques

Réalise moins d'un million de dollars de revenus ( SEK9M )

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

N'a pas de capitalisation boursière significative ( SEK261M )

Intervacc AB (publ) Concurrents

Biovica International

OM:BIOVIC B

SEK 210.2m

AcouSort

OM:ACOU

SEK 259.1m

Alzinova

OM:ALZ

SEK 192.4m

Saniona

OM:SANION

SEK 439.4m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Intervacc
Historique des cours de bourse
Prix actuel de l'action	SEK 4.30
Plus haut sur 52 semaines	SEK 10.46
Plus bas sur 52 semaines	SEK 2.90
Bêta	0.68
1Variation sur 1 mois	22.86%
Variation sur 3 mois	9.55%
Variation sur 1 an	4.88%
3Variation sur 3 ans	-94.14%
Variation sur 5 ans	-62.11%
Évolution depuis l'introduction en bourse	-44.16%

Nouvelles et mises à jour récentes

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

Jun 08

Recent updates

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Dec 15

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

Jun 01

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

May 17

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

Feb 28

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Feb 01

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Dec 10

Rendement pour les actionnaires

	IVACC	SE Biotechs	SE Marché
7D	13.2%	0.7%	1.1%
1Y	4.9%	24.7%	21.0%

Rendement vs Industrie: IVACC a sous-performé le secteur Swedish Biotechs qui a rapporté 25.7 % au cours de l'année écoulée.

Rendement vs marché: IVACC a sous-performé le marché Swedish qui a rapporté 21.3 % au cours de l'année écoulée.

Volatilité des prix

Is IVACC's price volatile compared to industry and market?
IVACC volatility
IVACC Average Weekly Movement	6.9%
Biotechs Industry Average Movement	8.6%
Market Average Movement	5.7%
10% most volatile stocks in SE Market	12.0%
10% least volatile stocks in SE Market	3.3%

Cours de l'action stable: IVACC n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de IVACC ( 7% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1983	15	Jonas Sohlman	www.intervacc.se

Intervacc AB (publ) développe de nouveaux vaccins vétérinaires pour les animaux en Suède. Le portefeuille de produits de la société comprend Stangvac, un vaccin contre la gourme équine pour les chevaux ; INV274, des antigènes pour un vaccin contre Strep. suis pour le traitement des porcelets ; et INV412, un vaccin à composants multiples pour protéger contre plusieurs bactéries qui causent la mastite pour le traitement des vaches.

Intervacc AB (publ) Résumé des fondamentaux

Comment les bénéfices et les revenus de Intervacc se comparent-ils à sa capitalisation boursière ?
IVACC statistiques fondamentales
Capitalisation boursière	SEK 325.67m
Bénéfices(TTM)	-SEK 102.76m
Recettes(TTM)	SEK 8.94m

36.4x

Ratio P/S

-3.2x

Ratio P/E

Le site IVACC est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
IVACC compte de résultat (TTM)
Recettes	SEK 8.94m
Coût des recettes	SEK 23.11m
Marge brute	-SEK 14.17m
Autres dépenses	SEK 88.59m
Les revenus	-SEK 102.76m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

Aug 29, 2024

Résultat par action (EPS)	-1.36
Marge brute	-158.59%
Marge bénéficiaire nette	-1,149.75%
Ratio dettes/capitaux propres	0.06%

Quelles ont été les performances à long terme de IVACC?

Voir les performances historiques et les comparaisons

IVACC Aperçu des actions

Récompenses

Analyse des risques

Intervacc AB (publ) Concurrents

OM:BIOVIC B

SEK 210.2m

OM:ACOU

SEK 259.1m

OM:ALZ

SEK 192.4m

OM:SANION

SEK 439.4m

Historique des prix et performances

Nouvelles et mises à jour récentes

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

New major risk - Share price stability

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

We're Not Worried About Intervacc's (STO:IVACC) Cash Burn

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Independent Director recently sold kr29m worth of stock

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

New 90-day high: kr76.60

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)